Particularly, the immunotherapy with interferon α-2a or, alternatively, treatment with interferon α and bevacizumab, an anti-VEGF monoclonal antibody, can be used to delay the onset of tumor progression. The gene discussed is VEGFA; the disease is neoplasm.